Compensation of Existing Disease
In examining current approaches to the compensation and prevention of asbestos-associated diseases, particular emphasis is placed on the utilization (or lack of it) of the biomedical scientific data base in accomplishing these objectives. It should be emphasized that, as with many other occupationally induced disorders, the asbestos-associated diseases are best dealt with by prevention through control of exposures to airborne concentrations of asbestos dust. In addition to the human costs of these diseases, no scheme of compensation can provide adequate disincentive for industry which would lead to the prevention of these conditions; this is due in large part to the long period of latency between relevant exposure and clinical manifestations of these diseases; however, recognizing that past exposures have produced these injuries, society must be committed to the provision of just resolution of claims by injured workers. Disease-specific approaches to federal legislation on compensation are not optimal in reaching the objective of equitable and timely awards for all workers who develop diseases as a consequence of their employment. The inadequacies of the legislation on black lung have received considerable attention and have been the subject of periodic controversy, often focusing on questions of cost effectiveness and equity. Currently, in the US Congress, legislation dealing with asbestos-associated diseases is being debated, undoubtedly related to overwhelming public and economic pressure. In recent months the opinion has often been expressed that the present system is strikingly inadequate in meeting the needs of individuals who have developed asbestos-associated diseases treated with My Canadian Pharmacy.